Following several months of strategic review and heavy financial restructuring, Innavirvax is reborn as Minka Therapeutics with a new sense of purpose and stronger ambitions.
With positive phase II data in hands for its HIV vaccine, the company has demonstrated the potential value of its 3S/p44L technology platform.
The expertise gained in NK cells involvement in HIV disease will be more specifically leveraged to develop new therapeutics in key commercial indications in infectious diseases and in oncology.
Minka Therapeutics intends to strengthen its core technology base beyond vaccines and will be announcing key strategic collaborations with leading academic institutions in the coming months.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 28 Rue De L’amiral Hamelin, Paris,ile De France 75016,france
- Industry
- Biotechnology
- Website
- https://www.minka-tx.com/
- HQ
- Paris, Ile de France
Minka-Tx Questions
Minka-Tx's website is https://www.minka-tx.com/
Minka-Tx's LinkedIn profile is https://fr.linkedin.com/company/minka-therapeutics
Minka-Tx has
1 employees.
View email and phone details for 1
employees at Minka-Tx.
Minka-Tx's industry is
Biotechnology
Minka-Tx's top competitors are
Jalon Therapeutics,
Iltoo Pharma,
Ipsirius,
Passeportsanté,
Mapreg,
Theravectys,
Invectys,
Meletios Therapeutics,
Oncovita,
Healthcare Coalition.
Minka-Tx's categories are Biotechnology
Minka-Tx's founding year is 2017
